SARS-CoV-2 Mpro-IN-41 (Compound 7e) is an orally active inhibitor targeting COX-2 and SARS-CoV-2 Mpro, with respective IC50 values of 9.66 µM and 13.24 µM. It also demonstrates inhibitory activity against COX-1 (IC50: 46.11 µM). This compound significantly suppresses the expression of inflammation-related cytokines such as TNF-alpha, IL-6, and IL-1beta, exhibiting anti-inflammatory properties. By selectively inhibiting COX-2 and SARS-CoV-2 Mpro, SARS-CoV-2 Mpro-IN-41 exerts both anti-inflammatory and antiviral effects, making it a potential candidate for research in inflammation and COVID-19 treatment.
Formula:
C27H23ClN4O3S
Target:
COX|||SARS-CoV
* VAT and and shipping costs not included. Errors and price changes excepted
